Cohen R L, Niclas J, Lee W M, Wun T C, Crowley C W, Levinson A D, Sadler J E, Shuman M A
Cancer Research Institute, University of California, San Francisco 94143.
J Biol Chem. 1989 May 15;264(14):8375-83.
Expression of plasminogen activators (PA) has been reported to be associated with invasive tumor growth and increased metastatic ability. In order to delineate changes in PA and PA inhibitor (PAI) expression that accompany cellular transformation, we studied oncogene-containing variants of the Rat-1 cell line. We report here that transfection of the oncogenes v-src, erbB, c-myc, v-myc, N-myc, and EJras into these cells does not result in detectable PA activity in conditioned media or cell extracts. In addition, Northern blot analysis fails to demonstrate urokinase mRNA in Rat-1 cells or transfectants. Moreover, cells transformed by EJras and v-src but not other oncogenes secrete an active placental-type PAI, PAI-2. Using inducible EJras constructs, we find that increased PAI-2 gene expression is detectable within 6-12 h after treatment with the inducing agent. Peak expression of PAI-2 mRNA is increased 10-15-fold over base line, and high levels are maintained for at least 72 h. In contrast to the results with PAI-2, secretion of endothelial-type PAI-1 into conditioned media is sharply down-regulated by several oncogenes. Thus, we have found that PAI-1 and PAI-2 are independently regulated in transformed variants of Rat-1 cells. The specific induction of PAI-2 in cells transformed by oncogenic ras and src suggests that this protease inhibitor may have a previously unsuspected role in malignancy.
据报道,纤溶酶原激活剂(PA)的表达与肿瘤的侵袭性生长及转移能力增强有关。为了阐明细胞转化过程中PA及其抑制剂(PAI)表达的变化,我们研究了含癌基因的大鼠1细胞系变体。我们在此报告,将癌基因v-src、erbB、c-myc、v-myc、N-myc和EJras转染到这些细胞中,在条件培养基或细胞提取物中未检测到PA活性。此外,Northern印迹分析未能在大鼠1细胞或转染细胞中检测到尿激酶mRNA。而且,由EJras和v-src转化而非其他癌基因转化的细胞分泌一种活性胎盘型PAI,即PAI-2。使用可诱导的EJras构建体,我们发现用诱导剂处理后6-12小时内可检测到PAI-2基因表达增加。PAI-2 mRNA的峰值表达比基线增加了10-15倍,并维持高水平至少72小时。与PAI-2的结果相反,几种癌基因可使内皮型PAI-1分泌到条件培养基中的水平急剧下调。因此,我们发现PAI-1和PAI-2在大鼠1细胞的转化变体中受到独立调节。致癌性ras和src转化的细胞中PAI-2的特异性诱导表明,这种蛋白酶抑制剂可能在恶性肿瘤中具有先前未被怀疑的作用。